

To: (10)(2e) 0 (10)(2e) (10)(2e) (10)(2e) @minvws.nl
Cc: (10)(2e) (10)(2e) @minvws.nl; (10)(2e) (10)(2e) (10)(2e) (10)(2e) @minvws.nl
From: (10)(2e) @gllcmedical.com
Sent: Mon 5/18/2020 3:04:40 PM
Subject: Re: Covid-19 test-strategy?
Received: Mon 5/18/2020 3:04:42 PM

Dear (10)(2e)

Thank you very much for getting back to me, and for your guidance.

With appreciation

(10)(2e)

On 18/05/2020 17:00, (10)(2e) 1 (10)(2e) (10)(2e) wrote:

Dear (10)(2e),

Thank you for your email. All offers concerning COVID-testing should be addressed to (10)(2e) @nfu.nl.

Best regards,

(10)(2e) (10)(2e)
 Projectleider Testcapaciteit Covid-19
 Telefoon: 06- (10)(2e)

Van: (10)(2e) <(10)(2e)@gllcmedical.com>
Datum: zaterdag 16 mei 2020 11:14 AM
Aan: (10)(2e) (10)(2e) (10)(2e) <(10)(2e)@minvws.nl>
Onderwerp: Covid-19 test-strategy?

Dear (10)(2e)

I am currently looking for the responsible team for your Covid-19 test-strategy planning, and hope you can kindly guide me in the right direction?

We have recently released a high quality, rapid test-kit for IgG and IgM antibodies against SARS-CoV-2 (Colloidal Gold-based) to be used by front-line healthcare professionals (nurses, doctors, etc.) to identify either whether a person has been infected and is now past the infection period, or if the person is currently infected with active virus, with high probability of the virus spreading and infecting others.

In collaboration with our ISO-certified kit-developer we have to date conducted more than (10)(2a) random tests combined with (10)(2a) – both indicating an accuracy rate better than 99%. By late May we're expecting the first comprehensive, independent clinical study performed by (10)(2a) with the initial data-release indicating >94% sensitivity and >98% specificity.

In parallel, we are providing samples to a number of National Medicine Agencies and their microbiology/virology labs - in (10)(2a) for additional independent performance validation. If there may be an interest in potentially adding a high quality and easy-to-use supplemental tool to your regional or national testing-arsenal in the long-term fight against SARS-CoV-2, I'll happily send you a number of samples (i.e. 50) for your own testing, validation and comparison with existing or planned testing-methods.

Looking forward to hearing from you.

Rgds

(10)(2e)

